首页VRX • SWX
Valeant製藥國際公司
CHF 21.44
5月10日, GMT+2 22:05:00 · CHF · SWX · 免责声明
股票在CH上市的证券总部位于CA
昨日收盘价
CHF 21.44
年度波幅
CHF 21.44 - CHF 21.44
市值
24.85亿 USD
市盈率
-
股息率
-
CDP 气候变化得分
D
市场资讯
财务信息
损益表
收入
净收入
(USD)2024年3月年同比变化
收入
21.53亿10.75%
经营支出
12.14亿6.96%
净收入
-6400.00万68.16%
净利润率
-2.9771.28%
每股收益
0.5911.72%
息税折旧摊销前利润
6.19亿13.37%
有效税率
-11.59%
总资产
负债总额
(USD)2024年3月年同比变化
现金及短期投资
7.33亿41.51%
总资产
269.13亿5.77%
负债总额
270.87亿7.06%
权益总额
-1.74亿
发行在外的股份
3.67亿
市净率
-7.05
资产回报率
2.75%
资本回报率
3.37%
现金净变动
(USD)2024年3月年同比变化
净收入
-6400.00万68.16%
来自运营的现金
2.11亿37.01%
投资现金
-7300.00万6.41%
融资现金
-3.40亿-139.44%
现金净变动
-2.07亿-245.00%
自由现金流
3.11亿23.41%
简介
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell. Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada. Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
成立时间
1959
员工数量
20,270
一探究竟
您可能感兴趣的股票
此列表是根据近期的搜索内容、关注的证券以及其他活动生成的。了解详情

所有数据和信息均按“原样”提供,仅供个人参考,并非金融建议,不可用于交易目的,亦不可用于提供投资、税务、法律、会计或其他方面的建议。Google 并非投资顾问,也不是金融顾问,并且对此列表中的任何一家公司或该等公司发行的所有证券不发表任何看法、建议或观点。在进行任何交易之前,请先咨询您的经纪人或金融代表,以便核实价格。了解详情
用户还搜索了
搜索
清除搜索内容
关闭搜索框
Google 应用
主菜单